AppOmni and Cisco Partner to Extend SaaS Security with End-to-End Zero Trust From Endpoint to the Application
Cisco selects AppOmni to join its Global Price List as part of its SolutionsPlus Program for easy procurement by global customers and resellers
AppOmni, the leader in SaaS security today announced a significant partnership that combines the company’s Zero Trust Posture Management (ZTPM) solution with Cisco’s Security Service Edge (SSE) technology suite to enable zero trust principles at the application layer in Security-as-a-Service (SaaS) applications. The combined solution provides organizations with end-to-end zero trust from the endpoint to the application and greatly improves security in complex SaaS installations, with enhanced visibility and monitoring into everything from configurations to user behaviors. With a secure environment for all cloud-based SaaS applications, enterprises can seamlessly implement zero trust principles to secure data from endpoint to SaaS.
“We’re honored to partner with Cisco to extend zero trust to SaaS for organizations worldwide—Cisco is one of the world’s great companies, and this partnership gives us a new level of access to a massive, worldwide customer base,” said AppOmni co-founder and chief technology officer, Brian Soby. “Just as Cisco Security Service Edge offers users an exceptional user experience and protected access from any device to anywhere, AppOmni’s Zero Trust Posture Management capabilities close critical gaps at the application level, such as misconfigurations in access controls, unchecked privileges, data leaks, and overlooked third-party integrations.”
AppOmni perfectly complements Cisco’s outstanding technology capabilities and market leadership, and the partnership brings AppOmni’s distinctive approach to SaaS security to Cisco customers and partners. As part of this ground-breaking partnership, AppOmni has also been selected to join a privileged group of independent software vendors (ISVs) on Cisco’s Global Price List (GPL) as part of Cisco’s SolutionsPlus Program. This arrangement extends the longtime relationship between the two companies—Cisco Investments backed the company in 2022—and offers a range of benefits to channel partners and customers alike. While technologies from the two companies are perfectly complementary, extending Cisco’s Zero Trust offering to include comprehensive SaaS Security and the inclusion in the GPL greatly simplifies and speeds the technology acquisition process for mutual customers. Additionally, Cisco’s Value-Added Reseller (VAR) community will have the ability to extend AppOmni solutions to their customers as part of Cisco’s SolutionsPlus Program.
“This complex operating environment demands continuous improvement, and we believe that can only be achieved with optimal collaboration—that’s exactly what this partnership delivers,” said Chris Sullivan, Director, Strategic Partnerships at AppOmni. “At AppOmni, we’ve worked hard to carve out a unique approach to SaaS security and develop a sterling reputation for both technology leadership and customer service. Cisco Secure Access Service Edge leverages the principles of Zero Trust Network Access to enforce strict access controls based on user identity and context. AppOmni perfectly complements this strategy at the application layer, and this combination represents the first complete application of zero trust principles to secure SaaS deployments.”
Learn more about how you can partner with AppOmni to drive innovation in SaaS security with technology already trusted by 4 of the Fortune 10 across technology, healthcare, banking and security.
About AppOmni
AppOmni is the leader in SaaS Security and simplifies protection for business-critical SaaS applications. With AppOmni, security teams and SaaS application owners quickly secure their mission-critical and sensitive data from attackers and insider threats. The AppOmni SaaS Security Platform continuously scans SaaS APIs, configurations, and ingested audit logs to deliver complete data access visibility, secure identities and SaaS-to-SaaS connections, detect threats, prioritize insights, and simplify compliance reporting. Four of the Fortune 10 and global enterprises across industries trust AppOmni to secure their SaaS applications.
Visit AppOmni.com, @AppOmni on LinkedIn, and watch SaaS security videos on YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107350434/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moutai's Global Brand Cultural Event Concludes in Italy22.12.2024 18:10:00 CET | Press release
The 2024 Global Brand Cultural Event hosted by Kweichow Moutai Group recently concluded successfully in Italy. Leveraging liquor as a cultural bridge between East and West, the event charted new pathways and milestones for Chinese brands, exemplified by Kweichow Moutai Group, in their global outreach. It also fostered deeper cultural exchange and mutual understanding between China and Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241222852417/en/ Gao Shan introduced Moutai to the guests at the event in Rome. (Photo: Business Wire) As part of the event, Moutai organized two grand themed tasting dinners in Milan and Rome. Gao Shan, Chairman of the Labor Union of Kweichow Moutai Distillery (Group) Co., Ltd., highlighted Italy's longstanding support in Moutai’s international journey, noting that the brand has been exported to Italy since the 1970s. Quoting Italian President Sergio Mattarella during his visit to China, Ga
Andersen Global styrker sin tilstedeværelse i Den Dominikanske Republik med tilføjelse af Valumonics22.12.2024 14:27:00 CET | Pressemeddelelse
Andersen Global forbedrer sine muligheder i Den Dominikanske Republik gennem en samarbejdsaftale med Valumonics, en virksomhed med speciale i værdiansættelse, fusioner og opkøb, udformning og implementering af finansiel strategi, ejendomsplanlægning og selskabsret. Valumonics blev grundlagt i 2010 af administrerende partner Tomás Fernández W. og har kontor i Santo Domingo. Valumonics arbejder med virksomheder, finansielle institutioner, investeringsselskaber og enkeltpersoner inden for en bred vifte af brancher og servicerer kunder på både lokale og internationale markeder. "Vores mål er at give kunderne uafhængige og tværfaglige integrerede tjenester," siger Tomás. "Vi ser frem til at skabe stærke forretningsrelationer med medlems- og samarbejdsvirksomhederne i Andersen Global og være en strategisk rådgiver for familier og førende virksomheder på det dominikanske marked." Global Chairman og CEO for Andersen Mark L. Vorsatz tilføjer: "Den Dominikanske Republik har en af de hurtigst v
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom